Pelabresib (CPI-0610), 10mM/1mL

Pelabresib (CPI-0610) is a potent and selective benzoisoxazoloazepine BET bromodomaininhibitor with an IC50 of 39 nM for BRD4-BD1 in TR-FRET assay and currently undergoing human clinical trials for hematological malignancies. CPI-0610 inhibits the expression of Nuclear receptor binding SET domain protein 3 (NSD3)target genes.